Articles
Can we market non-commercially viable orphan drugs?

Can we market non-commercially viable orphan drugs?

Oliver Timmis questions whether the pharma industry can market non-commercially viable orphan drugs, as our rare disease focus continues. Rare diseases were historically neglected by the pharmaceutical industry, because it was not commercially...

Articles
Contracts in clinical trials in emerging region: Asia Pacific

Contracts in clinical trials in emerging region: Asia Pacifi...

Tarun Pandotra explores the sometimes forgotten, but extremely important, aspect of clinical trials: the contract, including negotiations, budget and signing. There are many things to plan when considering to conduct a clinical trial. Not so long ago contract was one…

Articles
Challenges with real-world evidence to support HTA

Challenges with real-world evidence to support HTA

Tarang Sharma, expert in health economics and HTA, speaks with pharmaphorum on the challenges associated with using real-world evidence in HTA decision making. The emerging need for real-world evidence in HTA decision making is becoming apparent as regulators seek reassurance that...

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Oncology
Cancer cell

Building a Phase I oncology centre

The question is not whether an institution should ultimately develop Phase Ia capability. It is when the organisation is ready.

Patients

R&D